维普期刊资源整合服务平台（V6.5）

69篇 您的检索式：作者名="Athyros A"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management 显示文摘	K Athyros VG Karagiannis A	2010	Nutr Metab Cardiovasc Dis2010，20，2：	1
2	Statins and renal function in patients with diabetes mellitus显示文摘	Athyros V G Papageorgiou A A Elisaf M	2003	Curr Med Res Opin2003，19，7：	1
3	Endothelial function,arterial stiffness and lipid lowering drugs显示文摘	Athyros VG Karagiannis A	2007	Expert Opin Ther Targets2007，11，9：	1
4	Non-alcoholic fatty liver disease in type 2 diabetes : patho- genesis and treatment options 显示文摘	TZIOMALOS K ATHYROS V G KARAGIANNIS A	2012	Current Vascular Phar- macology2012，10，2：	1
5	Do we needto consider inflammatory markers when we treat ather-osclerotic disease显示文摘	Athyros VG Kakafika AI Karagiannis A	2008	Atherosclerosis2008，200，1：	1
6	Non-alcoholic fatty liver disease in type 2 diabetes:pathogenesis and treatment options 显示文摘	Tziomalos K Athyros VG Karagiannis A	2012	Curr Vasc Pharmacol2012，10，2：	1
7	Triglyceridcs and vascular risk: insights from epidemiological data and interventional studies 显示文摘	TZIOMALOS K ATHYROS VG KARAGIANNIS A	2009	Curt Drug Targets2009，10，4：	1
8	Pheochromocytoma:an update on genetics andmanagement显示文摘	KARAGIANNIS A MIKHAILIDIS DP ATHYROS VG	2007	Endocr Relat Cancer2007，14，4：	1
9	Pheoehromoey- toma: an update on genetiee and management显示文摘	Karagiannis A Mikhailidis D P Athyros V G	2007	Etdoer Relat Caneer2007，14，4：	1
10	Attaining United Kingdom-European Atherosclerosis Society low density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Sludy显示文摘	Athyros V G Mikhailidis D P Papageorgiou A A	2002	Curr Med Res Opin2002，18，8：	1
11	Statins and renal function in patients with diabetes mellitus显示文摘	Athyros V G Papageorgiou A A Elisaf M	2003	Curr Med Res Opin2003，19，7：	1
12	Atorvastatin: safety and tolera- bility显示文摘	Athyros VG Tziomalos K Karagiannis A	2010	Expert Opin Drug Saf2010，9，4：	1
13	Do we need to consider inflammatory markers when we treat atherosclerotic disease 显示文摘	Athyros VG Kakafika AI Karagiannis A	2008	Atherosclerosis2008，200，1：	1
14	Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease : a subgroup a- nalysis of the GREek Atorvastatin and Coronary - heart - disease Evaluation (GREACE) study 显示文摘	Athyros V G Elisaf M Papageorgiou A A	2004	Am J Kidney Dis2004，43，4：	1
15	Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease显示文摘	PEHLIVANIDIS A N ATHYROS V G DEMITRIADIS D S	2001	Atherosclerosis2001，157，2：	1
16	Pheo- chromocytoma: an update on genetics and management 显示文摘	Karagiannis A Mikhailidis DP Athyros VG	2007	Endocr Relat Cancer2007，14，4：	1
17	Effects of lipid- lowering agents on inflammation, haemostasis and blood pressure显示文摘	Tziomalos K Karagiannis A Athyros VG	2014	Curr PharmDes2014，20，40：	1
18	Anti inflammatory effects of fibrates: an overview显示文摘	Tziomalos K Athyros V G Karagiannis A	2009	Current Medicinal Chemistry2009，16，6：	1
19	Lipid- lowering agents and new onset diabetes mel- litues 显示文摘	Athyros VG Tziomalos K Karagiannis A	2010	Expert Opln Pharmacoth2010，11，12：	1
20	Omega-3fatty acids:how can they be used in secondary prevention-显示文摘	Tziomalos K Athyros VG Karagiannis A	2008	Curr Atheroscler Rep2008，10，6：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示